AOD-9604
Also known as: Anti-Obesity Drug 9604, Tyr-hGH Fragment 177-191
A modified fragment of human growth hormone studied for fat metabolism without growth-promoting effects.
Overview
AOD-9604 is a synthetic peptide fragment corresponding to the C-terminus of human growth hormone (amino acids 177-191) with an added tyrosine at the N-terminus. It was developed to isolate the lipolytic (fat-burning) properties of HGH without its growth-promoting or diabetogenic effects.
Mechanism of Action
AOD-9604 mimics the lipolytic fragment of HGH, stimulating lipolysis and inhibiting lipogenesis. It acts on beta-3 adrenergic receptors in adipose tissue, enhancing fat oxidation without affecting blood glucose or IGF-1 levels.
Pharmacokinetics
Rapid absorption following subcutaneous injection with peak levels within 15-30 minutes. Short half-life of approximately 30-60 minutes.
Dosing Protocols
Note: These are research protocols from literature. This is not medical advice.
Standard Protocol
250-300 mcg
Once daily
12 weeks
Morning administration, fasted
Stacking Recommendations
Peptides that may be combined based on complementary mechanisms in research settings.
Research Areas
Key Research Findings
- 1Australian clinical trials showed modest but significant weight loss vs placebo
- 2No effect on IGF-1 levels, distinguishing it from HGH
- 3Demonstrated cartilage regeneration properties in joint studies
- 4FDA GRAS status granted for food applications
Side Effects & Contraindications
Reported Side Effects
- Injection site reactions
- Headache (rare)
Contraindications
- Pregnancy
- Active cancer
Safety Considerations
Generally well-tolerated. No significant adverse effects on glucose metabolism or growth hormone pathways observed.
Storage Requirements
Store lyophilized at -20C. Reconstituted stable at 2-8C for 30 days.
Scientific References
- 1